ALK in house dust mite-drive in China
ALK approaches the market with a treatment for the most commercially important allergi. The company’s pill against house dust mite allergy could be launched in EU and Japan in 2015, with the US market following in 2016, and the first step toward the massive Chinese market has just been taken, says ALK’s top chief.
By Leonora Beck
The market for drugs to treat house dust mite allergy is becoming more visible on the horizon for ALK, following initiation of clinical studies in the EU, Japan and the US - so visible that the Danish allergy group is now taking the first steps toward the Chinese market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
ALK's Grastek launched in Canada
For abonnenter
FDA panel supports ALK approval
For abonnenter
ALK Chief: This is why we will conquer the US
For abonnenter
